Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study

Psychopharmacology

Volumn 225, Issue 3, 2013, Pages 519-530

  Ogasa, Masaaki ^a,b   Kimura, Tatsuya ^a   Nakamura, Mitsutaka ^c   Guarino, John ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

Atypical antipsychotics; Clinical trial; Drug therapy; Lurasidone; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO;

ADULT; AKATHISIA; ARTICLE; BACKACHE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT CHANGE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; THIAZOLES; YOUNG ADULT;

EID: 84873710953     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2838-2     Document Type: Article

References (28)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272
2. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
3. Bostwick JR, Guthrie SK, Ellingrod VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29:64-73
4. Correll CU, Druss BG, Lombardo I, O'Gorman C, Harnett JP, Sanders KN, Alvir JM, Cuffel BJ (2010) Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 61:892-898
5. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV (SCID). American Psychiatric Press, Washington, DC
6. Guy W (ed.) (1976) ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare Pub. No. (ADM) 76-338. National Institute of Mental Health, Rockville, MD
7. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19-28
8. International Conference on Harmonisation (ICH) (1996) ICH harmonised tripartite guideline: guideline for good clinical practice. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf. Accessed 17 Jan 2012
9. 1A receptor activity. J Pharmacol Exp Ther 334:171-181
10. Kay SR, Fiszbein A, Opler L (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
11. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW (2005) Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psych 62:1305-1312
12. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
13. Latuda® (lurasidone HCl) Tablets US prescribing information. http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed 28 October 2010.
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
15. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009b) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429-447
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
17. Lindenmayer J-P, Grochowski S, Hyman RB (1995) Five factor model of schizophrenia: replication across samples. Schizophr Res 14:229-234
18. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A (2011) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo and olanzapine-controlled study. Am J Psychiatry 168:957-967
19. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172
20. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829-836
21. Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(suppl 4):8-13
22. Potkin SG, Ogasa M, Cucchiaro J, Loebel A (2011) Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 132:101-107
23. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK (1993) The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 50:85-94
24. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233
25. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol (Berl) 124:57-73
26. Sernyak MJ, Rosenheck RA (2008) Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr Serv 59:567-569
27. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
28. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122-1129